

Dermatomycoses Market - A Global and Regional Analysis: Focus on Drug Type and Region - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/DA9680E2C704EN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: DA9680E2C704EN

Abstracts

The global dermatomycoses market is witnessing substantial growth driven by the rising incidence of superficial fungal infections, growing prevalence of immunocompromised patients, and increasing awareness of hygiene and dermatologic care.

Dermatomycoses are fungal infections of the skin, hair, and nails caused primarily by Trichophyton, Microsporum, and Epidermophyton species. The global disease burden continues to grow across tropical and subtropical regions, where humidity, poor hygiene, and overcrowding contribute to high infection rates. Expanding availability of topical and systemic antifungal treatments, coupled with diagnostic innovations, is strengthening the dermatomycoses market worldwide.

The dermatomycoses market is supported by consistent advancements in antifungal formulations and treatment approaches. Topical antifungal agents such as azoles, allylamines, and morpholine derivatives remain the frontline therapies, while systemic antifungals, including triazoles and polyenes, are used for severe or recurrent infections. Leading pharmaceutical companies are developing nanopharmaceutical drugs and liposomal antifungal formulations that enhance dermal absorption, minimize toxicity, and improve treatment adherence. Additionally, the growing adoption of combination antifungal therapies is improving treatment outcomes by reducing recurrence and resistance, marking a significant evolution in the dermatomycoses market.

Technological progress is accelerating market transformation. Advanced diagnostic tools—particularly digital PCR (dPCR) and molecular assays—enable precise fungal DNA detection and quantification, facilitating early diagnosis and targeted therapy. The proliferation of e-pharmacy platforms and OTC antifungal products is improving access to affordable treatment options. Furthermore, global public health initiatives promoting

personal hygiene and infection prevention, especially in high-humidity regions, are supporting the expansion of the dermatomycoses market.

Despite promising developments, the dermatomycoses market faces key challenges such as rising antifungal resistance, recurrence due to incomplete therapy, and limited innovation in novel antifungal targets. Long-term use of systemic antifungals also poses concerns regarding hepatotoxicity and drug–drug interactions. However, increasing investment in nanotechnology-based drug delivery systems, the emergence of broad-spectrum antifungal molecules, and the integration of AI-driven diagnostic platforms are expected to mitigate these limitations and drive long-term growth.

The competitive landscape of the dermatomycoses market features major players such as Kaken Pharmaceutical Co., Ltd., Novartis AG, Glenmark Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Bayer AG, and Galderma. These companies are strengthening their market position through R&D collaborations, geographic expansion, and product innovation. Strategic focus on developing new formulations, expanding dermatology portfolios, and leveraging digital platforms for patient engagement will continue to shape competition within the dermatomycoses market.

Looking ahead, the dermatomycoses market is expected to expand steadily through 2035, driven by continuous advancements in nanopharmaceutical technologies, molecular diagnostics, and global health awareness. The increasing adoption of combination therapies, early diagnostic tools, and OTC treatment options will ensure improved clinical outcomes and market sustainability.

Market Segmentation:

Segmentation 1: by Drug Type

Topical Antifungals

Oral/Systemic Antifungals

Combination Therapies

Others

Segmentation 2: by Region

North America

Europe

Asia-Pacific

Rest-of-the-World

The dermatomycoses market is expected to evolve with the introduction of advanced nano pharmaceutical antifungal drugs, precise digital PCR-based diagnostic tools, and patient-centric treatment innovations. Rising consumer awareness, improved healthcare accessibility, and continuous research in fungal biology will define the future growth trajectory of the dermatomycoses market.

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

This report will be delivered in 7-10 working days.

Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note

1. GLOBAL DERMATOMYCOSES MARKET: INDUSTRY ANALYSIS

1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
 1.3.1 Impact Analysis
1.4 Patent Analysis
 1.4.1 Patent Filing Trend (by Country)
 1.4.2 Patent Filing Trend (by Year)
1.5 Regulatory Landscape
1.6 Ongoing Clinical Trials
1.7 Market Dynamics
 1.7.1 Overview
 1.7.2 Market Drivers
 1.7.3 Market Restraints
 1.7.4 Market Opportunities

2. GLOBAL DERMATOMYCOSES MARKET, BY DRUG TYPE, \$MILLION, 2024-2035

2.1 Topical Antifungals
2.2 Oral/Systemic Antifungals
2.3 Combination Therapies
2.4 Others

3. GLOBAL DERMATOMYCOSES MARKET, BY REGION, \$MILLION, 2024-2035

3.1 North America
 3.1.1 Market Dynamics
 3.1.2 Market Sizing and Forecast
 3.1.3 North America Dermatomycoses Market, by Country

3.1.3.1 U.S.

3.2 Europe

3.2.1 Market Dynamics

3.2.2 Market Sizing and Forecast

3.2.3 Europe Dermatomycoses Market, by Country

3.2.3.1 U.K.

3.2.3.2 France

3.2.3.3 Germany

3.2.3.4 Italy

3.2.3.5 Spain

3.3 Asia-Pacific

3.3.1 Market Dynamics

3.3.2 Market Sizing and Forecast

3.3.3 Asia-Pacific Dermatomycoses Market, by Country

3.3.3.1 Japan

3.3.3.2 China

3.3.3.3 South Korea

3.3.3.4 Australia

3.3.3.5 India

3.4 Rest-of-the-World

3.4.1 Market Dynamics

3.4.2 Market Sizing and Forecast

4. GLOBAL DERMATOMYCOSES MARKET, COMPETITIVE LANDSCAPE AND COMPANY PROFILES

4.1 Competitive Landscape

4.1.1 Mergers and Acquisitions

4.1.2 Partnership, Alliances and Business Expansion

4.1.3 New Offerings

4.1.4 Regulatory Activities

4.1.5 Funding Activities

4.2 Company Profiles

4.2.1 Kaken Pharmaceutical Co., Ltd.

4.2.1.1 Overview

4.2.1.2 Top Products / Product Portfolio

4.2.1.3 Top Competitors

4.2.1.4 Target Customers/End-Users

4.2.1.5 Key Personnel

- 4.2.1.6 Analyst View
- 4.2.2 Novartis AG
 - 4.2.2.1 Overview
 - 4.2.2.2 Top Products / Product Portfolio
 - 4.2.2.3 Top Competitors
 - 4.2.2.4 Target Customers/End-Users
 - 4.2.2.5 Key Personnel
 - 4.2.2.6 Analyst View
- 4.2.3 Glenmark Pharmaceuticals Inc.
 - 4.2.3.1 Overview
 - 4.2.3.2 Top Products / Product Portfolio
 - 4.2.3.3 Top Competitors
 - 4.2.3.4 Target Customers/End-Users
 - 4.2.3.5 Key Personnel
 - 4.2.3.6 Analyst View
- 4.2.4 Sun Pharmaceutical Industries Ltd.
 - 4.2.4.1 Overview
 - 4.2.4.2 Top Products / Product Portfolio
 - 4.2.4.3 Top Competitors
 - 4.2.4.4 Target Customers/End-Users
 - 4.2.4.5 Key Personnel
 - 4.2.4.6 Analyst View
- 4.2.5 Teva Pharmaceutical Industries Ltd.
 - 4.2.5.1 Overview
 - 4.2.5.2 Top Products / Product Portfolio
 - 4.2.5.3 Top Competitors
 - 4.2.5.4 Target Customers/End-Users
 - 4.2.5.5 Key Personnel
 - 4.2.5.6 Analyst View
- 4.2.6 Bayer AG
 - 4.2.6.1 Overview
 - 4.2.6.2 Top Products / Product Portfolio
 - 4.2.6.3 Top Competitors
 - 4.2.6.4 Target Customers/End-Users
 - 4.2.6.5 Key Personnel
 - 4.2.6.6 Analyst View
- 4.2.7 Galderma
 - 4.2.7.1 Overview
 - 4.2.7.2 Top Products / Product Portfolio

- 4.2.7.3 Top Competitors
- 4.2.7.4 Target Customers/End-Users
- 4.2.7.5 Key Personnel
- 4.2.7.6 Analyst View

5. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Dermatomycoses Market (by Scenario), \$Million, 2024, 2030, and 2035

Figure: Global Dermatomycoses Market, 2024 and 2035

Figure: Global Dermatomycoses Market Key Trends, Impact Analysis, 2023-2035

Figure: North America Dermatomycoses Market, \$Million, 2023-2035

Figure: Europe Dermatomycoses Market, \$Million, 2023-2035

Figure: Asia-Pacific Dermatomycoses Market, \$Million, 2023-2035

Figure: Rest-of-the-World Dermatomycoses Market, \$Million, 2023-2035

List Of Tables

LIST OF TABLES

Table: Market Snapshot

Table: Market Dynamics

Table: Global Dermatomycoses Market (by Drug Type), \$Million, 2024-2035

Table: Global Dermatomycoses Market (by Region), \$Million, 2024-2035

I would like to order

Product name: Dermatomycoses Market - A Global and Regional Analysis: Focus on Drug Type and Region - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/DA9680E2C704EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DA9680E2C704EN.html>